Hookipa Q3 net loss narrows to $13.8M; cash $60M; Phase 2 eseba-vec enrollment complete (68 pts)

HOOKIPA Pharma Inc.

2024-Q3 EPS reported -$1.48 vs consensus -$1.30 ▼ miss (-13.5%)

Net loss $13.8M vs $19.1M YoY; revenue $4.7M (down from $6.9M) on Roche collaboration termination.
Cash $60.0M at Sep 30, 2024 (from $117.5M Dec 2023); received $5M milestone from Gilead for HB-500 dosing.
Phase 2 eseba-vec + pembrolizumab in HPV+ HNSCC enrolled 68 patients ahead of schedule; updated data at SITC 2024.
First patients dosed in MSKCC Investigator Initiated Trial of eseba-vec as adjuvant therapy for HNSCC.
Leadership: Malte Peters appointed CEO, Terry Coelho CFO in July; reverse stock split effected 1:10.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.